Study, Build, Design, Translate.
The Grousbeck Gene Therapy Center is an academic research center devoted to the broadening of therapeutic gene transfer in modern medicine. Our focus is on internal and collaborative preclinical and clinical research studies, technology development, and enabling resources for the community.
Vandenberghe Lab
The Vandenberghe Lab is the Grousbeck Gene Therapy core laboratory focused on developing and translating genetic therapies to the clinic with an emphasis on blindness and other neurosensory disorders. Researchers in the Vandenberghe lab work at the intersection of medicine, virology, engineering, immunology, synthetic and systems biology to innovate genetic medicine.
Vector Core
The Gene Transfer Vector Core (GTVC) is to provide high quality research-grade viral vector preparations to support basic research and preclinical gene therapy studies for academia and industry. GTVC has its primary expertise in adeno-associated viral vector (AAV) preparation, qualification, and application.
News
June 5, 2020 AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity
January 2, 2019 Nerea Zabalenta Lasarte, PhD joins the lab from the University of Navarra where she worked on liver-directed gene and genome editing therapies in the lab of Gloria González-Aseguinolaza.
September 2, 2018 Amanda Dudek graduates from the Harvard Virology Graduate Program on her work on AAV entry factors. Congratulations Amanda!
Upcoming Events

Director
Luk H. Vandenberghe, PhD
Luk H. Vandenberghe, PhD, is an Associate Professor at Harvard Medical School and Associate Member of the Broad Institute of Harvard and MIT in Boston, MA, USA. He directs the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear Infirmary in Boston, USA, a part of the the Ocular Genomics Institute, a bench to bedside research program to study, diagnose, and develop treatments for diseases of the eye.